875781-45-6

Basic information

• Product Name: 2-bromo-7-iodo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine
• Synonyms: 2-bromo-7-iodo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine;2-bromo-7-iodo-5-(4-methylbenzenesulfonyl)-5H-pyrrolo[2,3-b]pyrazine;2-bromo-7-iodo-5-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyrazine
• CAS NO: 875781-45-6
• Molecular Formula: C₁₃H₉BrIN₃O₂S
• Molecular Weight: 478.11
• Product Categories: CHIRAL CHEMICALS
• Mol File: 875781-45-6.mol

Chemical Properties

• Boiling Point: 560.1 °C at 760 mmHg
• Flash Point: 292.6 °C
• Appearance: /
• Density: 2.11 g/cm³
• Vapor Pressure: 1.41E-12mmHg at 25°C
• Refractive Index: 1.777
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-bromo-7-iodo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-7-iodo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine(875781-45-6)
• EPA Substance Registry System: 2-bromo-7-iodo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine(875781-45-6)

Safety Data

• Hazardous Substances Data: 875781-45-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-bromo-7-iodo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine is used as a building block in organic synthesis for the creation of diverse chemical structures. Its unique functional groups and reactivity make it a valuable component in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-bromo-7-iodo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine is utilized as a key intermediate in the development of novel drug molecules. Its presence in the molecular structure can impart important properties such as increased lipophilicity and bioactivity, which are crucial for drug discovery and development.
Used in Drug Discovery and Development:
2-bromo-7-iodo-5-tosyl-5H-pyrrolo[2,3-b]pyrazine is employed as a potentially valuable tool in drug discovery and development due to its unique structural features and reactivity. The presence of halogen atoms in the molecule can enhance its interaction with biological targets, making it a promising candidate for the design of new therapeutic agents.

InChI:InChI=1/C13H9BrIN3O2S/c1-8-2-4-9(5-3-8)21(19,20)18-7-10(15)12-13(18)16-6-11(14)17-12/h2-7H,1H3

Upstream product

• 875781-43-4 2-bromo-5H-pyrrolo[2,3-b]pyrazine 
• 875781-42-3 N-(5-bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-yl)acetamide 
• 875781-41-2 5-bromo-3-((trimethylsilyl)ethynyl)pyrazine-2-amine 
• 875781-44-5 2-bromo-7-iodo-5H-pyrrolo[3,2-b]pyrazine 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1229583-75-8 2-bromo-7-(1H-indol-5-yl)-5-tosyl-5H-pyrrolo[3,2-b]pyrazine 
• 1229582-37-9 7-(1H-indol-5-yl)-2-(3,4,5-trimethoxyphenyl)-5H-pyrrolo[3,2-b]pyrazine 
• 875781-46-7 2-bromo-7-(2-methoxy-phenyl)-5-(toluene-4-sulfonyl)-5h-pyrrolo[2,3-b]pyrazine 

Relevant articles and documents

TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF

Disclosed herein is a tricyclic compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

Compounds used as JAK inhibitor, and use of compounds

The invention provides compounds used as a JAK inhibitor, and a use of the compounds, and concretely provides compounds (represented by formula (I)) with JAK inhibition activity or a stereoisomer, a geometric isomer, a tautomer, a racemate, a nitrogen oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and a medicinal composition including the compounds. The invention also discloses a use of the compounds or the medicinal composition thereof in the preparation of medicines used for treating autoimmune diseases or proliferative diseases.

MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES

Disclosed are methods for treating an individual infected with a retrovirus that comprise administering to the individual effective amounts of a mixed lineage kinase inhibitor and antiretroviral drug. In further aspects, disclosed are methods for treating an individual infected with a retrovirus that comprises administering an antiretroviral drug formulated into a crystalline nanoparticle comprising a surfactant, and a MLK inhibitor. Still further disclosed are methods for treating an individual infected with a retrovirus that comprises administering a composition comprising both an antiretroviral and MLK inhibitor formulated into a crystalline nanoparticle, which comprises a surfactant. Still further disclosed are compositions that comprise an antiretroviral drug, a MLK inhibitor, and a surfactant, wherein the composition is a crystalline nanoparticle. Compostions comprising MLK inhibitors with other drugs in nanoparticulate form, and methods of there use, are also disclosed.

BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE

Provided are compounds having an inhibitory effect on kinases including Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders that comprise the inhibition of Mixed Lineage Kinases.

MLK INHIBITORS AND METHODS OF USE

Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.

FUSED RING HETEROCYCLE KINASE MODULATORS

The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.